Compare Virgin Galactic Holdings, Inc. (SPCE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs GeneDx Holdings Corp — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.97 (market cap $474.50M), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: GeneDx Holdings Corp is far larger — about 5.4× Virgin Galactic Holdings, Inc.'s market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| SPCE | WGS | |
|---|---|---|
Market Cap | $474.50M | $2.56B |
Sector | Industrials | Technology |
52-Week High | $7.52 | $167.51 |
52-Week Low | $2.17 | $34.51 |
Enterprise Value | $438.48M | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Virgin Galactic (SPCE) trades at $3.13, up 2.96% with a bullish technical outlook from moving averages. The company continues to report significant losses with negative profit margins and cash flow, though recent quarters have shown earnings beats. Management targets positive cash flow by 2027, but commercial spaceflight delays to February 2027 create execution risk. Analyst sentiment is divided with 29% buy, 41% hold, and 29% sell ratings.
SPCE represents a high-risk, speculative opportunity in the emerging space tourism sector. The path to profitability remains distant with substantial cash burn, though strong ticket demand provides potential upside if execution improves. Key risks include ongoing dilution, high short interest, and the capital-intensive nature of space operations. Investors should weigh the long-term potential against persistent financial challenges.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
